Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma

Yeseul Kim; Seong Sik Bang; Jee Seungyun; PARK SEONGEON; Su-Jin Shin; Kiseok Jang

Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma

Recommendations

Search

Type: Academic journal

Author: Yeseul Kim Seong Sik Bang Jee Seungyun PARK SEONGEON Su-Jin Shin Kiseok Jang

Journal: 대한암학회 Cancer Research and Treatment Cancer Research and Treatment 제52권 제2호 KCI Accredited Journals

Published: 2020.1

Pages: 481 - 491 (11page)

Usage

Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma

Abstract· Keywords

Report Errors

Purpose Mesenchymal epithelial transition (MET) is a proto-oncogene that encodes a heterodimeric transmembrane receptor tyrosine kinase for the hepatocyte growth factor. Aberrant MET signaling has been described in several solid tumors—especially non-small cell lung cancer— and is associated with tumor progression and adverse prognosis. As MET is a potential therapeutic target, information regarding its prevalence and clinicopathological relevance is crucial. Materials and Methods We investigated MET expression and gene amplification in 113 gallbladder cancers using tissue microarray. Immunohistochemistry was used to evaluate MET overexpression, and silver/fluorescence in situ hybridization (ISH) was used to assess gene copy number. Results MET overexpression was found in 37 cases of gallbladder carcinoma (39.8%), and gene amplification was present in 17 cases (18.3%). MET protein expression did not correlate with MET amplification. MET amplification was significantly associated with aggressive clinicopathological features, including high histological grade, advanced pT category, lymph node metastasis, and advanced American Joint Committee on Cancer stage. There was no significant correlation between any clinicopathological factors and MET overexpression. No difference in survival was found with respect to MET overexpression and amplification status. Conclusion Our data suggested that MET might be a potential therapeutic target for targeted therapy in gallbladder cancer, because MET amplification was found in a subset of tumors associated with adverse prognostic factors. Detection of MET amplification by ISH might be a useful predictive biomarker test for anti-MET therapy.

No content found

References (38)

Add References

정규원 / 2019 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016 / Cancer Research and Treatment 51(2):417~430

Sharma A / 2017 / Gallbladder cancer epidemiology, pathogenesis and molecular genetics : recent update / World J Gastroenterol 23:3978~3998

Li M / 2014 / Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway / Nat Genet 46:872~876

Bengala C / 2010 / Sorafenib in patients with advanced biliary tract carcinoma : a phase II trial / Br J Cancer 102:68~72

Chiorean EG / 2012 / Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers : Hoosier Oncology Group GI06-101 / Oncologist 17:13

Recommendations

It is an article recommended by DBpia according to the article similarity. Check out the related articles!